In murine studies, the DPP-IV inhibitor vildagliptin was shown to switch lipid accumulation from the liver and skeletal muscle to adipose tissue, which is in line with the reduced skeletal muscle mass decline observed in T2DM patients [103,106]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.